Michael S. Perry, Hon BSc, DVM., PhD, a Venture Partner with Bay City Capital, is the Chief Development Officer of VIA Pharmaceuticals. Dr. Perry was the founder and Chief Executive Officer of Extropy Pharmaceuticals. He was also Chief Executive Officer of Pharsight (PHST), SyStemix, and Genetic Therapy, and served as a director on each of the companies’ boards. Prior to these positions, Dr. Perry was Global Head of R&D for Baxter BioScience, Vice President of Novartis Pharma and Vice President of Syntex Corporation. He currently serves as a member of the board of directors of Targeted Genetics (TGEN), American Xeno, Navon Pharmaceuticals, and as an observer for Itamar Medical. Dr. Perry holds an Honors BSc in Engineering/Physics from the University of Guelph, a DVM from the Ontario Veterinary College, and a PhD in Biomedical Pharmacology with specialization in cardiopulmonary medicine from the University of Guelph. Dr. Perry is also a graduate of The Executive/International Management Program at Harvard Business School.